Recruiting

Lymphovenous Bypass Procedure for Secondary Prevention of Lymphedema in Breast Cancer

This study aims to evaluate the effectiveness of the Lymphovenous Bypass (LVB) procedure compared to physiotherapy alone as secondary prevention of lymphedema in breast cancer patients undergoing axillary lymph node dissection.

ClinicalTrials.gov IDNCT07233863

PhaseNA

Enrollment136

SponsorDharmais National Cancer Center Hospital

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Lymphedema Arm

About this study

Interventions

Procedure: Lymphovenous bypass (LVB) — The Lymphovenous Bypass (LVB) procedure in this study is a microsurgical supermicrosurgery-based intervention specifically designed for the secondary prevention of breast cancer-related lymphedema following axillary lymph node dissection.

Primary outcomes

BCRL improvement rate (24 months)

Eligibility information

Inclusion Criteria: * Breast cancer patients aged ≥ 18 years with an ECOG score \> 1 * Breast cancer patients with post-axillary lymph node dissection diagnosed with stage 0 and I lymphedema. * Those who have never undergone lymphedema physiotherapy. Exclusion Criteria: * Patients with dermal backflow before axillary lymph node dissection (ALND). * Patients with breast cancer lymphedema who are unable to undergo a 24-month follow-up at Dharmais Cancer Hospital. * Patients with iodine allergy, severe asthma, decreased kidney function, pregnancy, or breastfeeding.

Study locations

Dharmais National Cancer Center, Jakarta, Jakarta Special Capital Region 11420 Indonesia

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-30.